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Mannish reactionAbstract A new and effective spectrophotometric method was developed for the determination of
adrenaline in pharmaceutical preparations for control purposes. The condensation of Mannish
reaction between 1 mol of adrenaline with new ligand, 5-benzimino-1,3,4-thiodiazole-2-thione (I)
in the presence of 1 mol of p-formaldehyde as the condensing agent with 15–25 ml of dioxin as sol-
vent took place. The precipitate yield was yellowish-brown colored. The new ligand was prepared
by the Schiff base reaction of 5-amino-3-H, 1,3,4-thiodiazole-2-thione and 1 mol of benzaldehyde in
15 ml of ethanol as solvent and one drop of glacial acetic acid. The accuracy and precision of this
method were determined by analyzed laboratory samples of adrenaline, the results show absolute
error ranging from 0.22 to +0.86 and relative errors ranging from ±1.4% to 8.6%. The calibra-
tion graph was linear in the range of 2–20 mg l1 for adrenaline with an S.D equal to 2.17%, and
RSD of 2.76% (n= 5; Conc. = 80 mg l1). This method was successfully applied for the adrenaline
determination in commercial pharmaceutical injections for the quality control.
ª 2011 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Adrenaline is a hormone and a neurotransmitter (Berecek and
Brody, 1982). Japanese chemist Jokichi Takamine and his
assistant Keizo Uenaka independently discovered adrenaline
in 1900 (Yamashima, 2003). Adrenaline is an active principleof the medulla of the suprarenal gland and is a drug used in
the treatment of cardiac arrest, heart block, asthma, nasal con-
gestion, hypotension, etc. It increases heart rate, constricts
blood vessels, dilates air passages and participates in the
ﬁght-or-ﬂight response of the sympathetic nervous system.
Chemically, epinephrine is a catecholamine, a monoamine
produced only by the adrenal glands from the amino acids
phenylalanine and tyrosine. HPLC is regulated by US pharma-
copeia (United State Pharmacopeia XXV, 2002) and China
pharmacopeia (China Pharmacopeia, 1995) as the ofﬁcial
method to assay the drug in injections. Epinephrine may be
quantitated in blood, plasma or serum as a diagnostic aid, to
monitor therapeutic administration or to identify the causative
agent in a potential poisoning victim. Endogenous plasma
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than 10 ng L1, but may increase by 10-fold during exercise
and by 50-fold or more during times of stress. Pheochromocy-
toma patients often have plasma epinephrine levels of
1000–10,000 ng L1. Parenteral administration of epinephrine
to acute-care cardiac patients can produce plasma concentra-
tions of 10,000–100,000 ng L1 (Baselt, 2008). Epinephrine
also leads to broad alterations throughout all organ systems
( Sircar, 2007). Epinephrine acts by binding to a variety of
adrenergic receptors. Adrenaline is a nonselective agonist of
all adrenergic receptors, including a1, a2, b1, b2, and b3 recep-
tors (Howard, 2008). Adrenaline in acetate buffer reacts with a
solid-phase reactor containing lead (IV) dioxide immobilized
in a polyester resin and the yield was continuously monitored
at 486 nm using a ﬂow injection spectrophotometric procedure
(Teixeira et al., 2002). A single channel FIA assembly is pro-
posed for the spectrophotometric determination of adrenaline
in aqueous sample solution, the method has been applied to
the determination of adrenaline in a pharmaceutical formula-
tion (Kojo and Martinez Calatayud, 1990). Berzas Nevado
et al. proposed a new rapid and successfully applied method
for the determination of adrenaline and dopamine in pharma-
ceuticals, on the basis of the hydrolysis of these compounds in
alkaline medium. The method was optimized by using a spec-
trophotometer operating at k = 390 nm as detector (Berzas
Nevado et al., 1996). The best conditions for the optimization
were established by square wave voltammetry. The best perfor-
mance was obtained with 50%:20%:15%:15% (m/m/m/m) as
the graphite powder:laccase:Nujol:ILs composition in
0.1 mol L1 acetate buffer solution pH 4.0. The analytical
curve was linear in the concentration range of 2.49 · 106–
2.27 · 104 mol L1 with a detection limit of 5.34 · 10
7 mol L1. The recovery of adrenaline in injectable samples
ranged from 96.3% to 101.6%. The results obtained for adren-
aline using the proposed biosensor and the United States Phar-
macopeia procedure were in agreement at the 95% conﬁdence
level (Franzoi et al., 2010). The design of an un segmented-ﬂow
injection manifolds for the simultaneous determination of
adrenaline and nor adrenaline two structurally related com-
pounds with overlapping spectra. An FIA manifold is pro-
posed for the simultaneous determination in which the
sample solution is directly injected into a carrier-reagent
stream of aqueous NaOH. The selected wavelengths (ﬁrst
derivative) were 394 and 342 nm, for noradrenaline and adren-
aline, respectively, with an integration time of 0.4 s. The cali-
bration graphs are linear over the range of 2.0–30 mg L1
for both drugs (Rivas et al., 1996).
The objective of this research was aimed at developing a
Spectrophotometric analytical method for the determinationScheme 1 The Schof adrenaline in pharmaceutical preparations for the quality
control purpose.
2. Experimental
2.1. Materials and measurements
All reagents and solvents obtained from commercial sources
were of high purity purchased from Fluka and BDH and no
further puriﬁcation was needed. Adrenaline hormone supplied
by the BDH and used as received, adrenaline (Epinephrine)
injection, 1 mg/1 mL, commercially available supplied by the
MISR Co., Egypt. IR spectra were recorded using KBr and
CsI discs in the range 4000–400 cm1 on FT-IR, Tests cane
Shimadzu model Spectrophotometer. UV–Vis spectra were
recorded using Shimadzu UV–Vis spectrophotometer with
quartz cells size 1 cm was used to measure the absorbance at
kmax of each adrenaline complex analyte.
3. Preparation of complexes
3.1. Synthesis of the ligand (Schiff base procedure)
1 mol of 5-amino-3-H, 1,3,4-thiodiazole-2-thione in 15 ml eth-
anol as solvent and 1 mol of benzaldehyde in 15 ml of ethanol
as solvent and one drop of glacial acetic acid was stirred and
heated to reﬂux for 2 h (Ortega-luoni et al., 2007), The crude
product was a yellowish-brown colored liquid, 5-benzimino-
1,3,4-thiodiazole-2-thione (I), Scheme 1.
3.2. Synthesis of adrenaline complexes (Mannish procedure)
1 mol of adrenaline hormone and 1 mol of p-formaldehyde as
condensing agent with 1 mol Schiff base yield, 5-benzimino-
1,3,4-thiodiazole-2-thione (I) with 15–25 ml of dioxin as sol-
vent, then heated to reﬂux for 2 h, Scheme 2.
3.3. Calibration graph
A standard calibration graph for adrenaline complexes (Fig. 1)
in the concentration range of 2–20 mg L1 was prepared and
used to determine the adrenaline concentration. Using the
Method of Least Squares (Miller and Miller, 2000) the regres-
sion equation (Y= Xb± a), where b is the slope = 0.0056, a
is the intercept =+0.00479, Y is the absorbance and X is the
concentration, was utilized for the calculation of unknown
concentrations in medicinal adrenaline injection samples. The
validity of the regression equation was tested by analyzing lab-
oratory injections. Beers law is valid within the concentrationiff base yield (I).
Scheme 2 The adrenaline complex, Mannish yield (II).
Figure 1 FT-IR spectrum of standard adrenaline.
Table 1 Analysis of laboratory standard adrenaline samples.
Sample No. Abs. Conc. (mg L1) Av. Conc. Absolute
error
Relative
error %
1 0.059 9.68 9.68 +0.32 +3.2
2 0.062 10.22 0.22 2.2
3 0.058 9.50 +0.50 +5.0
4 0.056 9.14 +0.86 +8.6
5 0.060 9.86 +0.14 +1.4
Table 2 Analysis of adrenaline (epinephrine) injection, 1 mg/
1 mL commercially available supplied by the MISR Co., Egypt.
Sample No. Abs. Conc.
(mg L1)
Av. Conc.
(mg L1)
S.D R.S.D%
1 0.451 79.68 78.50 2.17 2.76
2 0.442 78.07
3 0.438 77.36
4 0.455 80.39
5 0.436 77.00
S1002 S.A.H. Al-Ameriranges of adrenaline. The results are summarized in Table 1 for
laboratory injections. Samples of medicinal adrenaline injec-
tions samples were analyzed, the results are given in Table 2.
3.4. Stoichiometric ion complex formation
The adrenaline complexes with the ligand, 5-benzimino-1,3,4-
thiodiazole-2-thione was studied in solution using methanolas solvent, in order to determine M:L ratio in the prepared
complexes following continuous variation (Job’s) method
(Skooge et al., 2004). A series of solutions were prepared hav-
ing varied concentration, of adrenaline and 5-benzimino-1,3,4-
thiodiazole-2-thione ligand at total constant concentration of
103 M. The M:L ratio was found from the plot of absorbance
at kmax 312 nm of the formation complexes versus the mole
fraction.
3.5. Results and discussion
Adrenaline is a hormone and neurotransmitter (Berecek and
Brody, 1982). It increases heart rate, contracts blood vessels,
dilates air passages and participates in the ﬁght-or-ﬂight
response of the sympathetic nervous system (United State
Pharmacopeia XXV, 2002).
3.6. IR spectra
The standard adrenaline shows an overlapped band in the
region of 3400–3200 cm1 which could be assigned to V(NH)
and V(OH) vibrations (Tajen et al., 2004; Socrates, 1980).
Another absorptions at 2962 cm1 and (1500–1600 cm1)
referred to aliphatic V(C–H) and aromatic V(C‚C) vibrations
modes (Tajen et al., 2004; Socrates, 1980; Silversten and Web-
ster, 1998) (Fig. 1). Upon condensation of 5-benzimino-1,3,4-
thiodiazole-2-thione (Schiff base (I) with adrenaline in the
presence of condensing agent (p-formaldehyde), the appear-
ance of a V(C‚N) band at 1669 cm1, V(C‚S) at 1226 cm
1 and the broadening of V(O–H) mode in the range of
3518–3200 cm1 conﬁrm the formation of the Mannish base
(II). As well as the isomethene group in thiodiazole ring at
1535 cm1 as a strong band and C–N band at 1375 cm1
together with the above absorptions suggests good proof for
the formation of N–CH2–N mode, Fig. 2.
3.7. Electronic absorption spectra (UV–Vis)
Complex of adrenaline standard with Schiff base (I) of 5-ben-
zimino-1,3,4-thiodiazole-2-thione caused either bathochromic
or hypsochromic shifts. The standard solution of adrenaline
in acidiﬁed methanol (0.1 N) shows three peaks related to
charge transfer, and pﬁp* of benzenoid group at 205 and
282 nm, respectively, Fig. 3 (Dibbern et al., 2002; Kannappan
et al., 2006; Beraldom and Tosi, 1986). Upon condensation of
Figure 2 FT-IR spectrum of adrenaline complex.
Figure 5 Standard calibration graph for adrenaline complex.
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2-thione, the adrenaline complex exhibits two distinct peaks at
240 and 310 nm which are attributed to pﬁp* and overlapping
of nﬁp* with charge transfer due to the presence of chromo-
phore groups like C‚N, C‚S conjugates with heterocyclic
groups such as those observed in 1,3,4-thiodiazole, Fig. 4
(Kannappan et al., 2006; Silversten and Webster, 1998).
3.8. Analysis
A standard calibration graph for adrenaline complex solutions
Fig. 5 in the concentration range of 2–20 ppm was prepared
and used to determine the concentration of adrenaline. In
order to examine the accuracy and precision of the analysis
method, Tables 1 and 2 summarize the analysis of laboratory
sample and samples of medicinal adrenaline injections, the
results show an absolute error ranging from 0.22 to +0.86
and relative errors ranging from ±1.4% to 8.6%. TheFigure 3 UV–Vis spectrum of standard adrenaline.
Figure 4 UV–Vis spectrum of adrenaline complex.calibration graph was linear in the range of 2–20 mg L1 for
adrenaline with an S.D equal to 2.17%, and RSD of 2.76%
(n= 5; C= 80 mg l1). The proposed method was success-
fully applied to the determination of adrenaline in various
injections used in commercial pharmaceutical formulations
for the quality control purpose. The concentration measure-
ment was done using UV–Vis spectrophotometer at kmax
312 nm using 1 cm quartz cell (Fig. 4).
3.9. Structure of the product
This study concerns with the Spectrophotometric identiﬁcation
and determination of the adrenaline hormone as complex (II)
in pharmaceutical injections using Mannish reaction after the
preparation of Schiff base (I), 5-benzimino-1,3,4-thiodiazole-
2-thione, Scheme 1, heated to reﬂux for 2 h of benzaldehyde
and 5-amino-3-H, 1,3,4-thiodiazole-2-thione with 1 drop of
glacial acetic acid. Upon condensation of Schiff base (I), 5-
benzimino-1,3,4-thiodiazole-2-thione with 1 mol adrenaline in
the presence of 1 mol of p-formaldehyde as condensing agent
with 15–25 ml of dioxin as solvent. The precipitate yield was
yellowish-brown in color, Scheme 2. The stoichiometry of
the reaction between each adrenaline and ligand was investi-
gated under the recommended conditions and applying Job’s
method. The obtained results in Fig. 6 showed that a 1:1 prod-
uct was formed between adrenaline and ligand at kmax 312 nm,
and due to the phenolic nature of the adrenaline, it can be
readily coupled with the ligand according to Scheme 2, Figs.
1 and 2 (Dibbern et al., 2002).Figure 6 Continuous variation (Job’s method) for adrenaline:
ligand complex.
S1004 S.A.H. Al-AmeriAcknowledgment
The author are very grateful to Ass. Professor Mahmoud N.A.
Al-Jibouri/Chemistry Department/College of Science/Al-Mus-
tansiriyah University for many helpful discussions and sugges-
tions during this study.
References
Baselt, R., 2008. Disposition of Toxic Drugs and Chemicals in Man,
8th edition. Biomedical Publications, Foster City, CA, pp. 545–
547.
Beraldom, H., Tosi, L., 1986. Inorg. Chem. Acta 125, 127.
Berecek, K.H., Brody, M.J., 1982. Evidence for a neurotransmitter
role for epinephrine derived from the adrenal medulla. Am. J.
Physiol. 242 (4), H593–H601.
Berzas Nevado, J.J., Lemus Gallego, J.M., Buitrago Laguna, P., 1996.
Flow-injection spectrophotometric determination of adrenaline
and dopamine with sodium hydroxide. J. Pharm. Biomed. Anal.
14 (5), 571–577.
China Pharmacopeia, 1995, China Pharmacopeial Committee (Ed),
Chemical Engineering Press House, Beijing, p. 381.
Dibbern, H.W., Muller, R.M., Wirbitzki, E. 2002. UV and IR Spectra,
p. 603.
Franzoi, Ana Cristina, Vieira, Iolanda Cruz, Dupontba, Jairton, 2010.
Biosensors of laccase based on hydrophobic ionic liquids derived
from imidazolium cation. J. Braz. Chem. Soc. 21 (8),
1451–1458.
Howard, Shen, 2008. Illustrated pharmacology memory cards: phar-
mnemonics. Minireview, 4.
Kannappan, R., Tanase, S., Mutikainen, L., Turpeinen, U., Reedijk,
J., 2006. Polyhedron 25, 1646.Kojo, A., Martinez Calatayud, J., 1990. Spectrophotometric determi-
nation of adrenaline with an oxidative column in a FIA assembly.
J. Pharm. Biomed. Anal. 8 (8–12), 663–666.
Miller, James N., Miller, Jane C., 2000. Statistics and Chemometrics
for Analytical Chemistry, fourth ed. Prentice Hall, p. 125.
Ortega-luoni, Pedro, Vera, Leonel, Astudillo, Claudio, Guzmn,
Miguel, Ortega-Lopez, Pedro, 2007. Synthesis of metallic azo
derivatives of 2-amino-5-mercapto-1,3,4-thiodiazole. J. Chil.
Chem. Soc. 52 (1).
Rivas, G.A., Laredo Ortiz, S., Martinez Calatayud, J., 1996. Simul-
taneous determination of adrenaline and noradrenaline by ﬁrst
derivative spectrophotometry in a Fia assembly. Anal. Lett. 29 (12),
2115–2124.
Silversten, R.M., Webster, F.X., 1998. Spectroscopic Identiﬁcation of
Organic Compounds, sixth ed. Wiley, New York.
Sircar, Sabyasachi, 2007. Medical Physiology. Thieme Publishing
Group, p. 536.
Skooge, Douglas A., West, Donald M., James Holler, F., Crouch,
Stanley R. 2004. Fundamental of Analytical Chemistry, eighth ed.
BROOKS/COLE-THOMSON Learning, Belmont, CA, USA, p
805.
Socrates, G., 1980. Infrared Characteristic Group Frequencies. John
Wily and Sons, pp. 289–295.
Tajen, O., Bilge, C., Fethi, S., 2004. Turk. J. Chem. 28, 461–468.
Teixeira, Marcos F.S., Marcolino-Ju´nior, Luiz H., Fatibello-Filho,
Orlando, 2002. Flow injection spectrophotometric determination of
adrenaline in pharmaceutical formulations using a solid-phase
reactor containing lead (IV) dioxide immobilized in a polyester
resin. II Farmaco 57 (3), 215–219.
United State Pharmacopeia XXV. 2002, (Asian edition), Published by
Board of Trustees, p. 658.
Yamashima, T., 2003. Jokichi Takamine (1854–1922), the samurai
chemist, and his work on adrenalin. J. Med. Biogr. 11 (2), 95–102.
